Valuing clinical strategies early in development: A cost analysis of allogeneic peripheral blood stem cell transplantation

Bone Marrow Transplantation

Volumn 24, Issue 5, 1999, Pages 555-560

  Bennett, C L ^a,c   Waters, T M ^a   Stinson, T J ^a   Almagor, O ^a   Pavletic, Z S ^b   Tarantolo, S R ^b   Bishop, M R ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Economics; Hematologic neoplasms; Hematopoietic stem cell transplantation

Indexed keywords

ANTIINFECTIVE AGENT; COLONY STIMULATING FACTOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; METHOTREXATE;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST CONTROL; FEMALE; GRAFT VERSUS HOST REACTION; HEALTH CARE COST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALIZATION; HUMAN; HUMAN CELL; HYPERALIMENTATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RELAPSE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0032877607     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701945     Document Type: Article

References (28)

1. Welch HG. Valuing clinical strategies early in their development. Ann Int Med 1992; 116: 263-264.
2. Waters TM, Bennett CL, Pajeau TS et al. The costs and cost-effectiveness of bone marrow and peripheral blood stem cell transplantation: what do we know? Bone Marrow Transplant 1998; 21: 641-650.
3. van Hoef MEHM. The IBMTR and European Group for Blood and Marrow Transplantation initiate two timely joint projects. The IBMTR Newsletter of the IBMTR/ABMTR Statistical Center, Milwaukee, Wisconsin, July 1997.
4. Schmitz N, Dreger P, Suttorp M et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by fllgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666-1672.
5. Bensinger WI, Clift R, Martin P et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced malignancies: a retrospective analysis. Blood 1996; 88: 2794-2800.
6. Korbling M, Mirza N, Thall P et al. 100 HLA-identical allogeneic blood stem cell transplantations: The MD Anderson Cancer Center Experience. Bone Marrow Transplant 1997; 19 (Suppl. 1): S72 (Abstr. 84).
7. Garcia-Conde J, Martin-Gaitero MJ, Arbona C et al. High frequency of chronic graft versus host disease associated with unmodified PBPC transplants. Preliminary results of allogeneic CD34+ selected PBPC transplants. Blood 1996; 88: 261a.
8. Schmitz N, Bacigalupo A, Labopin M et al. Transplantation of allogeneic peripheral blood progenitor cells - the EBMT experience. Bone Marrow Transplant 1996; 17 (Suppl. 2): 40-46.
9. Korbling M, Fliedner TM. The evolution of clinical peripheral blood stem cell transplantation. Bone Marrow Transplant 1996; 17 (Suppl. 2): 4-11.
10. Beyer J, Schwella N, Zigsem J et al. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral blood progenitor cells or bone marrow: a randomized comparison. J Clin Oncol 1995; 13: 1328-1335.
11. Miflin G, Russell NH, Hutchinson RM et al. Allogeneic peripheral blood progenitor stem cell transplantation for hematologic malignancies: an analysis of kinetics of engraftment and GVHD risk. Bone Marrow Transplant 1997; 19: 9-13.
12. Russell JA, Brown C, Bowen T et al. Allogeneic blood cell transplants for hematological malignancy: preliminary comparison of outcomes with bone marrow transplantation. Bone Marrow Transplant 1996; 171: 703-708.
13. Azevedo WM, Aranha FJP, Gouvea JV et al. Allogeneic transplantation with blood stem cells mobilized by rhG-CSF for hematological malignancies. Bone Marrow Transplant 1995; 16: 647-653.
14. Gulati SC, Bennett CL. Granulocyte macrophage colony stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. Ann Int Med 1992; 116: 177-182.
15. Luce BR, Singer JW, Wechsler JM et al. Recombinant human granulocyte macrophage colony stimulating factor after autologous bone marrow transplantation for lymphoid cancer: an economic analysis of a randomized double-blind placebo controlled trial. Pharmacoeconomics 1994; 6: 42-48.
16. Bennett CL, George SL, Vose JM et al. Granulcoyte macrophage colony stimulating factor as adjunct therapy in relapsed lymphoid malignancy: implications for economic analyses of phase III clinical trials. Stem Cells 1994; 131: 414-420.
17. Smith TJ, Hillner BE, Schmitz N et al. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral blood progenitor cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 5-10.
18. Uyl-de-Groot CA, Richel DJ, Rutten FFH. Peripheral blood progenitor cell transplantation mobilised by r-metHuG-CSF (filgrastim): a less costly alternative to autologous bone marrow transplantation. Eur J Cancer 1994; 30A: 1631-1635.
19. Bennett CL, Armitage JL, Armitage GO et al. Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: 1987 through 1991. J Clin Oncol 1995; 13: 969-973.
20. Schulman KA. Economics of bone marrow transplantation. J Clin Oncol 1996; 14: 1409-1410.
21. Barr R, Furlong W, Henwood J et al. Economic evaluation of allogeneic bone marrow transplantation: a rudimentary model to generate estimates for the timely formulation of clinical policy. J Clin Oncol 1996; 14: 1413-40.
22. Pavletic ZS, Bishop MR, Tarantolo SR et al. Hematopoietic recovery after allogeneic blood stem cell transplantation compared to bone marrow transplantation in patients with hematologic malignancies. J Clin Oncol 1997; 15: 1608-1613.
23. Martin-Algarra S, Bishop MR, Tarantolo S et al. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs-host disease prophylaxis. Exp Hematol 1995; 23: 1503-1508.
24. Faucher C, Fortanier C, Viens P et al. Clinical and economic comparison of lenograstim-primed blood cells (BC) and bone marrow (BM) allogeneic transplantation, Bone Marrow Transplant 1998; 21 (Suppl. 3): S92-S98.
25. Pavletic ZS, Joshi SS, Pirruccello SJ et al. Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies. Bone Marrow Transplant 1998; 21: 33-41.
26. Kucharski AJ, Ghalie R, Greenstein S, Matuszewski K. The clinical effectiveness and financial impact of utilizing peripheral blood progenitor cells as rescue therapy following autologous bone marrow transplant. Int J Tech Assess Health Care 1996; 12: 172-179.
27. Korbling M, Przepiorka D, Huh YO et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-1665.
28. Storek J, Gooley M, Bensinger WI et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft versus host disease. Blood 1997; 90: 4705-4709.